Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections

Herpes simplex virus type-1 (HSV-1) is a neurotropic, double-stranded DNA virus that can cause a wide variety of diseases, including many ocular pathologies. It is one of the leading causes of infectious blindness in the United States. Because of its ubiquitous nature and its potential to cause seri...

Descripción completa

Detalles Bibliográficos
Autores principales: Koganti, Raghuram, Yadavalli, Tejabhiram, Shukla, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843252/
https://www.ncbi.nlm.nih.gov/pubmed/31658632
http://dx.doi.org/10.3390/microorganisms7100429
_version_ 1783468171176443904
author Koganti, Raghuram
Yadavalli, Tejabhiram
Shukla, Deepak
author_facet Koganti, Raghuram
Yadavalli, Tejabhiram
Shukla, Deepak
author_sort Koganti, Raghuram
collection PubMed
description Herpes simplex virus type-1 (HSV-1) is a neurotropic, double-stranded DNA virus that can cause a wide variety of diseases, including many ocular pathologies. It is one of the leading causes of infectious blindness in the United States. Because of its ubiquitous nature and its potential to cause serious ocular maladies, there is a significant need for more effective antiviral therapies against ocular HSV-1. In this review, we discuss the lifecycle of HSV-1 as it pertains to corneal infections and the clinically approved as well as emerging treatments to combat HSV-1 infections. We also highlight some newly identified host targets for the antiviral drug development.
format Online
Article
Text
id pubmed-6843252
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68432522019-11-25 Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections Koganti, Raghuram Yadavalli, Tejabhiram Shukla, Deepak Microorganisms Review Herpes simplex virus type-1 (HSV-1) is a neurotropic, double-stranded DNA virus that can cause a wide variety of diseases, including many ocular pathologies. It is one of the leading causes of infectious blindness in the United States. Because of its ubiquitous nature and its potential to cause serious ocular maladies, there is a significant need for more effective antiviral therapies against ocular HSV-1. In this review, we discuss the lifecycle of HSV-1 as it pertains to corneal infections and the clinically approved as well as emerging treatments to combat HSV-1 infections. We also highlight some newly identified host targets for the antiviral drug development. MDPI 2019-10-10 /pmc/articles/PMC6843252/ /pubmed/31658632 http://dx.doi.org/10.3390/microorganisms7100429 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Koganti, Raghuram
Yadavalli, Tejabhiram
Shukla, Deepak
Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title_full Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title_fullStr Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title_full_unstemmed Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title_short Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections
title_sort current and emerging therapies for ocular herpes simplex virus type-1 infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843252/
https://www.ncbi.nlm.nih.gov/pubmed/31658632
http://dx.doi.org/10.3390/microorganisms7100429
work_keys_str_mv AT kogantiraghuram currentandemergingtherapiesforocularherpessimplexvirustype1infections
AT yadavallitejabhiram currentandemergingtherapiesforocularherpessimplexvirustype1infections
AT shukladeepak currentandemergingtherapiesforocularherpessimplexvirustype1infections

Ejemplares similares